Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cabel

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 23, 2018
[Circulating tumour DNA: Current detection methods, use in radiotherapy and future development]J Castelli, L Cabel, F-C Bidard, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 11, 2017
Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?L Cabel, C Proudhon, P Mariani, et al.
NPJ Breast Cancer|June 12, 2026
Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancerS A Wander, C M Weipert, L Cabel, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|April 30, 2015
[Ductal carcinoma in situ treated with radiation therapy and additional boost]R Geiss, L Cabel, E Touboul, et al.
Journal of Thrombosis and Haemostasis : JTH|August 6, 2017
Circulating tumor cell count and thrombosis in metastatic breast cancerG Beinse, F Berger, P Cottu, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancerE Arnaud, P Vaflard, L Escalup, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancerL Cabel, F Berger, T Bachelot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept studyL Cabel, F Riva, V Servois, et al.
ESMO Open|May 22, 2021
HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancerL Cabel, C Bonneau, A Bernard-Tessier, et al.
British Journal of Cancer|April 3, 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutationJ-S Frenel, A Lusque, S Delaloge, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 23, 2018
[Circulating tumour DNA: Current detection methods, use in radiotherapy and future development]J Castelli, L Cabel, F-C Bidard, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 11, 2017
Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?L Cabel, C Proudhon, P Mariani, et al.
NPJ Breast Cancer|June 12, 2026
Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancerS A Wander, C M Weipert, L Cabel, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|April 30, 2015
[Ductal carcinoma in situ treated with radiation therapy and additional boost]R Geiss, L Cabel, E Touboul, et al.
Journal of Thrombosis and Haemostasis : JTH|August 6, 2017
Circulating tumor cell count and thrombosis in metastatic breast cancerG Beinse, F Berger, P Cottu, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancerE Arnaud, P Vaflard, L Escalup, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2025
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancerL Cabel, F Berger, T Bachelot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept studyL Cabel, F Riva, V Servois, et al.
ESMO Open|May 22, 2021
HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancerL Cabel, C Bonneau, A Bernard-Tessier, et al.
British Journal of Cancer|April 3, 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutationJ-S Frenel, A Lusque, S Delaloge, et al.
Pageof 2